Business Context and Reporting Period
This Form 8-K Current Report was filed by Globus Medical, Inc. on September 27, 2023. The filing discloses the entry into a material definitive credit agreement and the approval of a new stock repurchase program by the Board of Directors.
Key Financial Metrics and Agreements
- Credit Facility: Entered into an unsecured credit agreement with an aggregate commitment of $400 million.
- Expansion Option: Borrowers may request an increase in revolving commitments up to $200 million, or an unlimited amount if the Leverage Ratio is at least 0.25 to 1.00 below the required threshold.
- Interest Rates: Loans bear interest at the Base Rate or Term SOFR Rate plus an Applicable Margin. Margins range from 0.125% to 0.625% for Base Rate and 1.125% to 1.625% for Term SOFR, depending on the Leverage Ratio.
- Stock Repurchase Program: Authorized an additional $350 million for repurchasing Class A Common Stock.
- Total Repurchase Availability: Approximately $150.8 million remains from prior programs (announced in 2020 and 2022), bringing total available capital for buybacks to approximately $500.8 million.
- Funding Source: The Company intends to utilize cash reserves to fund the share repurchase program.
Material Changes and Covenants
The new Credit Agreement replaces or supplements prior financing arrangements and introduces specific financial and operational covenants:
- Financial Covenant: Includes a ratio of Funded Net Indebtedness to EBITDA.
- Restrictions: The agreement restricts the ability to incur additional indebtedness, create liens, make investments, merge, declare dividends, or make share repurchases (subject to exceptions).
- Guarantors: Obligations are guaranteed by NuVasive, Inc., NuVasive Clinical Services Monitoring, Inc., and Branch Medical Group, LLC.
- Term: The Credit Agreement terminates on September 27, 2028.
Outlook, Risks, and Management Commentary
Management indicated that the repurchase program will be executed consistent with a capital allocation strategy that prioritizes long-term business growth. The timing and volume of repurchases depend on market prices, general business conditions, and alternative investment opportunities. The program has no time limit and may be suspended or discontinued at any time.
Risks and Contingencies: The Credit Agreement contains customary events of default, including non-payment, misrepresentation, failure to perform covenants, cross-defaults, change of control, bankruptcy, and certain ERISA events.
Investor Verification Checklist
- Verify the current Leverage Ratio to determine the applicable interest rate margin and borrowing capacity.
- Confirm the exact amount of cash reserves available to fund the $350 million repurchase authorization without impacting operational liquidity.
- Review the specific definition of Funded Net Indebtedness to EBITDA in the Credit Agreement (Exhibit 10.1) to assess covenant headroom.
- Monitor future filings for actual share repurchase activity and any utilization of the credit facility.